<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590563</url>
  </required_header>
  <id_info>
    <org_study_id>AOS-C1000-02</org_study_id>
    <nct_id>NCT01590563</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Initial Efficacy of a Novel Intrauterine Device</brief_title>
  <official_title>A Study to Evaluate the Safety and Initial Efficacy of a Spherical Copper Intrauterine Contraceptive Device the IUB(tm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocon Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocon Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current intrauterine devices (IUD) pose such risks as uterine perforation during insertion,&#xD;
      malposition and expulsion. The investigated device, the IUB(tm) SCu300A is an IUD which is&#xD;
      inserted in a similar fashion into the uterus and takes a three dimensional spherical shape&#xD;
      while curving away from the fundus. Apart for an anticipated reduction in the rate of stated&#xD;
      complications, its smaller size and mallable characteristics are also expected to improve&#xD;
      user experience. The clinical trial is intended to evaluate the safety and initial efficacy&#xD;
      of this novel device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A copper IUD (intrauterine device or coil) is a type of intrauterine contraceptive device.&#xD;
      Most IUDs have a plastic T-shaped frame which is wrapped in copper wire and sleeves. The&#xD;
      device has to be fitted inside and removed from the uterine cavity by a doctor or qualified&#xD;
      medical practitioner. It remains in place the entire time pregnancy is not desired.&#xD;
&#xD;
      The IUD is a long acting reversible contraceptive, with different IUDs intended to last for&#xD;
      different lengths of time, usually between 3 and 10 years. The length of time that the device&#xD;
      lasts depends mainly on the amount of exposed copper, which is indicated, in square&#xD;
      millimeters, by a number in the name of each device (i.e., the Paragard T-380A has 380 square&#xD;
      millimeters of exposed copper).&#xD;
&#xD;
      The IUD is the world's most widely used method of reversible birth control, currently used by&#xD;
      over 175 million women.&#xD;
&#xD;
      The mechanism of IUDs is not well understood. It is known however that the presence of a&#xD;
      device in the uterus prompts the release of leukocytes and prostaglandins by the endometrium.&#xD;
      These substances are hostile to both sperm and eggs; the presence of copper increases the&#xD;
      spermicidal effect. The general medical consensus is that spermicidal and ovicidal mechanisms&#xD;
      are the only way in which IUDs work. Some physicians and medical texts have suggested they&#xD;
      may have a secondary effect of interfering with the development of pre-implanted embryos;&#xD;
      this secondary effect is considered more plausible when the IUD is used as emergency&#xD;
      contraception.&#xD;
&#xD;
      Second-generation copper-T IUDs have failure rates of less than 1% per year, and cumulative&#xD;
      10-year failure rates of 2-6%. A copper IUD may also be used as emergency contraception. If&#xD;
      an IUD is inserted within five days of unprotected intercourse, a woman's chance of pregnancy&#xD;
      is reduced to that of ongoing IUD users.&#xD;
&#xD;
      IUDs do not protect against STDs or PID.&#xD;
&#xD;
      Made from a shape memory alloy of a specific size and shape, the SCu300A IUB™ is inserted&#xD;
      through an insertion tube much like regular IUDs, however, when pushed out, in the uterus, it&#xD;
      takes a spherical shape. An important feature includes its downwards curving opposite to the&#xD;
      uterine fundus as it emerges out of the tube, minimizing the risk of perforation. The three&#xD;
      dimensional shape's elasticity allows for better amenability to the uterus, nullifying the&#xD;
      possibility of malposition and its final outer diameter reducing the probability of&#xD;
      expulsion. Lacking rigid or protruding segments and being significantly smaller than other&#xD;
      IUDs, the IUB™ is expected to reduce distortion and tissue irritation, possibly resulting in&#xD;
      less bleeding, discomfort and pain, leading to lower discontinuation rates. A thread is&#xD;
      attached to the IUB™ to allow easy removal.&#xD;
&#xD;
      The trialed IUB™ will be copper-based (Cu surface area of 300mm2).&#xD;
&#xD;
      This study aims to assess the IUB™'s safety and initial efficacy. Endpoints include the&#xD;
      assessment of changes in discomfort, pain and menorrhea, changes in the endometrium&#xD;
      discontinuation rates as well as user experience. These results will be used as regulatory&#xD;
      evidence and will also help in reaffirming the assumption that the IUB™'s design contributes&#xD;
      to lower complication and side effect rates.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intrauterine device</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of Uterine Perforation</measure>
    <time_frame>During installation</time_frame>
    <description>Uterine perforation is an established risk of IUD deployment which may cause certain health hazards. It is anticipated that the IUB(tm), through its form and deployment pattern, will reduce this risk.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy in Preventing Pregnancy</measure>
    <time_frame>12 months</time_frame>
    <description>Prevention of pregnancy will be measured. Pregnancy rates are expected to be comparable to current IUDs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Malposition, Expulsion.</measure>
    <time_frame>12 months</time_frame>
    <description>Expulsion and malposition are established risks involved with IUD use. Occurrence of these risks may drastically reduce effectiveness. It is expected that the IUB(tm) form will reduce these risks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>SCu300A IUB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insertion of a spherical IUD (intrauterine device) with one year follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IUD</intervention_name>
    <description>Insertion of a spherical IUD, one year follow-up</description>
    <arm_group_label>SCu300A IUB</arm_group_label>
    <other_name>SCu300A IUB(tm)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult female aged 25-42&#xD;
&#xD;
          -  Free willing to fully comply with treatment process&#xD;
&#xD;
          -  Healthy women&#xD;
&#xD;
          -  Married or in a steady relationship. Blood hemoglobin &gt;11.5gr%&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or suspicion of pregnancy&#xD;
&#xD;
          -  Use of other contraception methods&#xD;
&#xD;
          -  Abnormalities of the uterus resulting in distortion of the uterine cavity&#xD;
&#xD;
          -  Acute current or past history of pelvic inflammatory disease, or current behavior&#xD;
             suggesting a high risk for pelvic inflammatory disease&#xD;
&#xD;
          -  Postpartum endometritis or postabortal endometritis in the past 3 months&#xD;
&#xD;
          -  Known or suspected uterine or cervical malignancy&#xD;
&#xD;
          -  Genital bleeding of unknown etiology&#xD;
&#xD;
          -  Mucopurulent cervicitis&#xD;
&#xD;
          -  Wilson's disease&#xD;
&#xD;
          -  Allergy to any component of IUB™&#xD;
&#xD;
          -  A previously placed IUD that has not been removed&#xD;
&#xD;
          -  Known intolerance or allergy to copper and/or copper IUDs&#xD;
&#xD;
          -  Medication that may interfere with the subject's ability to complete the protocol&#xD;
&#xD;
          -  Any other significant disease or condition that could interfere with the subject's&#xD;
             ability to complete the protocol&#xD;
&#xD;
          -  A history of alcohol or drug abuse&#xD;
&#xD;
          -  known infection with human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C&#xD;
&#xD;
          -  Planned pregnancy during the follow-up period&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
&#xD;
          -  Anemia of any kind or blood hemoglobin lower than 11.5gr%.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beata Szoczei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synexus Hungary Kft.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synexus Hungary Limited</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 20, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2012</study_first_posted>
  <results_first_submitted>November 5, 2013</results_first_submitted>
  <results_first_submitted_qc>October 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2015</results_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ocon Medical Ltd.</investigator_affiliation>
    <investigator_full_name>Dana Raveh Arbel</investigator_full_name>
    <investigator_title>VP Clinical</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SCu300A IUB</title>
          <description>Insertion of a spherical IUD (intrauterine device) with one year follow-up</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>simple uterine hyperplasia - not related</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SCu300A IUB</title>
          <description>Insertion of a spherical IUD (intrauterine device) with one year follow-up</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.9" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Contraception Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rates of Uterine Perforation</title>
        <description>Uterine perforation is an established risk of IUD deployment which may cause certain health hazards. It is anticipated that the IUB(tm), through its form and deployment pattern, will reduce this risk.</description>
        <time_frame>During installation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigated Device Group</title>
            <description>Group inserted the investigated device - the IUB SCu300A</description>
          </group>
        </group_list>
        <measure>
          <title>Rates of Uterine Perforation</title>
          <description>Uterine perforation is an established risk of IUD deployment which may cause certain health hazards. It is anticipated that the IUB(tm), through its form and deployment pattern, will reduce this risk.</description>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NR" upper_limit="18.1%"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy in Preventing Pregnancy</title>
        <description>Prevention of pregnancy will be measured. Pregnancy rates are expected to be comparable to current IUDs.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SCu300A IUB</title>
            <description>Insertion of a spherical IUD (intrauterine device) with one year follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Preventing Pregnancy</title>
          <description>Prevention of pregnancy will be measured. Pregnancy rates are expected to be comparable to current IUDs.</description>
          <units>Number of pregnancies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Malposition, Expulsion.</title>
        <description>Expulsion and malposition are established risks involved with IUD use. Occurrence of these risks may drastically reduce effectiveness. It is expected that the IUB(tm) form will reduce these risks.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>SCu300A IUB</title>
            <description>Insertion of a spherical IUD (intrauterine device) with one year follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Malposition, Expulsion.</title>
          <description>Expulsion and malposition are established risks involved with IUD use. Occurrence of these risks may drastically reduce effectiveness. It is expected that the IUB(tm) form will reduce these risks.</description>
          <units>Number of cases</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>SCu300A IUB</title>
          <description>Insertion of a spherical IUD (intrauterine device) with one year follow-up</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <description>Investigated device was removed, condition not caused by investigated device.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Beata Szoczei, MD</name_or_title>
      <organization>Synexus Hungary</organization>
      <phone>+36 1 436 7330</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

